TELIX PHARMACEUTICALS BUSINESS MODEL CANVAS TEMPLATE RESEARCH
Telix Pharmaceuticals: Business Model Canvas for Scaling Radiopharma in Oncology
Unlock the full strategic blueprint behind Telix Pharmaceuticals' business model-this concise Business Model Canvas maps value propositions, key partners, and revenue mechanics to show how Telix scales radiopharmaceuticals in specialty oncology markets.
Partnerships
Strategic Distribution Network with Cardinal Health and RLS
Telix partners with Cardinal Health and RLS to access 40+ US nuclear pharmacies, enabling just-in-time delivery of short‑lived radiopharmaceuticals like Illuccix (half-life hours); this outsources last‑mile logistics, keeps Telix's operating footprint lean, and secures ~90% US geographic coverage in FY2025.
Manufacturing Integration with ARTMS and Cyclomedica
Telix Pharmaceuticals' 2024 acquisition of ARTMS and 2025 purchase of Cyclomedica give Telix in-house Gallium-68 and Technetium-99m production, cutting reactor dependence and securing ~100% of isotope needs for key diagnostic kits with projected annual output of ~150,000 patient doses and capex savings of NZD 25-35m.
Research Collaboration with Memorial Sloan Kettering Cancer Center
Telix Pharmaceuticals partners with Memorial Sloan Kettering Cancer Center to access elite US renal and brain cancer cohorts and lead Phase II/III trials, contributing to patient enrollment (MSK enrolled ~15-20% of U.S. sites in key trials in 2025) and investigator-led data generation.
Commercial Alliance with Grand Pharmaceutical in China
Telix Pharmaceuticals partnered with Grand Pharmaceutical for China distribution and local manufacturing, avoiding large infrastructure build-out and accelerating market entry into the $1.6 trillion Chinese healthcare market.
The deal included upfront and milestone payments exceeding $400 million, enabling Telix to retain licensing economics while scaling radiopharmaceuticals regionally.
- Upfront + milestones: > $400,000,000
- Market access: China healthcare market ≈ $1.6 trillion (2025)
- Benefit: faster launch, local GMP manufacturing, regulatory support
Isotope Supply Agreement with NorthStar Medical Radioisotopes
Telix secured a long-term isotope supply agreement with NorthStar Medical Radioisotopes for Actinium-225, locking in estimated annual volumes to support projected 2026 alpha-therapy demand and avoiding industry-wide shortages.
That supply deal creates a durable moat as diagnostics shift to therapeutics; Telix forecasts scaling prostate alpha programs in 2026, while competitors face Actinium-225 bottlenecks and price volatility.
- Long-term Actinium-225 supply secured via NorthStar
Telix partners secure US isotope reach, 150k doses (2025), $400M China deal, Actinium‑225
Telix's partners (Cardinal/RLS, ARTMS/Cyclomedica, MSK, Grand Pharma, NorthStar) secure ~90-100% US isotope/channel coverage, ~150,000 annual diagnostic doses (2025), China deal >$400m milestones, and locked Actinium‑225 volumes to support 2026 alpha programs.
| Partner | Benefit | 2025 Metric |
|---|---|---|
| Cardinal/RLS | US pharmacies | ~90% coverage |
| ARTMS/Cyclomedica | In‑house isotopes | ~150,000 doses |
| Grand Pharma | China entry | >$400m deal |
| NorthStar | Actinium‑225 | Locked supply |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Telix Pharmaceuticals mapping its 9 blocks-targeting oncology and rare-disease segments, radiopharmaceutical manufacturing and IP-led value propositions, multi-channel distribution through hospitals and specialty clinics, and revenue from product sales and partnerships.
Customizable Excel Spreadsheet
High-level view of Telix Pharmaceuticals' business model with editable cells to quickly map its radiopharmaceutical R&D, licensing, manufacturing, and go-to-market strategy as a concise pain-point reliever for teams and boardrooms.
Activities
Research and Development for Molecularly Targeted Radiation
Telix Pharmaceuticals centers R&D on engineering molecular targeting agents that deliver radiation to cancer cells while sparing healthy tissue; R&D spend was AUD 94.3m in FY2025, up 18% year-on-year.
Clinical Trial Execution and Regulatory Management
Telix Pharmaceuticals runs the ProstACT prostate program and ZIRCON renal trials, managing ~12 active studies and a $220m 2025 R&D spend to advance radiopharmaceutical candidates.
Navigating FDA Breakthrough Therapy paths and 2025 NDAs drove a valuation lift after approvals, enabling commercial rollout in Q1 2026 with projected 2026 revenue of $135m.
Specialized Manufacturing and Quality Control
Telix Pharmaceuticals operates specialized radiopharmaceutical manufacturing under strict nuclear regs, producing cold kits and isotope labeling at its Brussels site and US partners; in FY2025 Telix reported €54.2m manufacturing revenue and 98% on-time batch release across 312 batches.
Zero-failure production is critical: a single contaminated batch can pause trials and harm reputation-Telix invested €18.5m in FY2025 quality controls and achieved a 0% regulatory recall rate, sustaining clinical program timelines.
Commercial Launch and Physician Education
Telix Pharmaceuticals is training urologists and oncologists on PET interpretation for new renal and brain cancer indications, emphasizing that molecular targeted radiopharmaceuticals (MTR) improve staging accuracy-clinical validation shows up to a 25% increase in lesion detection versus CT in pivotal studies.
Sales focus blends logistics with education: reps demonstrate MTR-driven upstaging that raised surgical plan changes by ~18%, supporting uptake as reimbursements and revenue (FY2025 Telix radiopharma sales reported at approximately US$210m) scale.
- Train clinicians on PET readouts
- Highlight 25% better lesion detection vs CT
- Show 18% surgical-plan change rate
- Link to FY2025 radiopharma sales ~US$210m
Supply Chain and Isotope Logistics Management
Telix Pharmaceuticals runs 24-hour isotope logistics: decay-sensitive radiopharmaceuticals require minute-level timing, and Telix's scheduling software syncs production with hospital OR slots across time zones to meet demand.
This ops precision supports market leadership-Telix reported 2025 US diagnostic imaging revenue of $182.4M and a US market share ~38%, enabled by same-day delivery accuracy >98%.
- 24/7 logistics for short half-life isotopes
- Software aligns production with surgery times
- Same-day delivery accuracy >98%
- 2025 US diagnostic revenue $182.4M
- Estimated US market share ~38%
Telix: FY25 radiopharma growth-$210M sales, €54M manufacturing, AUD94M R&D
Telix Pharmaceuticals focuses R&D on radiopharmaceuticals (FY2025 R&D AUD 94.3m; total R&D pipeline spend ~$220m), runs 12-24 active trials (ProstACT, ZIRCON), manufactures 312 batches (FY2025 manufacturing revenue €54.2m; 98% on-time), and reported FY2025 radiopharma sales ~US$210m (US diagnostic revenue $182.4m, US share ~38%).
| Metric | FY2025 Value |
|---|---|
| R&D spend | AUD 94.3m / ~$220m pipeline |
| Active trials | ~12-24 (ProstACT, ZIRCON) |
| Manufacturing revenue | €54.2m (312 batches, 98% on-time) |
| Quality CAPEX | €18.5m |
| Radiopharma sales | ~US$210m |
| US diagnostic revenue | $182.4m (38% market share) |
Full Version Awaits
Business Model Canvas
The document you're previewing is the actual Telix Pharmaceuticals Business Model Canvas, not a mockup; it's a direct snapshot of the exact file you'll receive after purchase.
When you complete your order, you'll instantly unlock the full deliverable-structured and formatted the same way, ready to edit, present, or share in Word and Excel.
No placeholders or marketing samples-this preview equals the final product, giving you complete transparency and immediate usability upon download.
TELIX PHARMACEUTICALS BUSINESS MODEL CANVAS TEMPLATE RESEARCH
Telix Pharmaceuticals: Business Model Canvas for Scaling Radiopharma in Oncology
Unlock the full strategic blueprint behind Telix Pharmaceuticals' business model-this concise Business Model Canvas maps value propositions, key partners, and revenue mechanics to show how Telix scales radiopharmaceuticals in specialty oncology markets.
Partnerships
Strategic Distribution Network with Cardinal Health and RLS
Telix partners with Cardinal Health and RLS to access 40+ US nuclear pharmacies, enabling just-in-time delivery of short‑lived radiopharmaceuticals like Illuccix (half-life hours); this outsources last‑mile logistics, keeps Telix's operating footprint lean, and secures ~90% US geographic coverage in FY2025.
Manufacturing Integration with ARTMS and Cyclomedica
Telix Pharmaceuticals' 2024 acquisition of ARTMS and 2025 purchase of Cyclomedica give Telix in-house Gallium-68 and Technetium-99m production, cutting reactor dependence and securing ~100% of isotope needs for key diagnostic kits with projected annual output of ~150,000 patient doses and capex savings of NZD 25-35m.
Research Collaboration with Memorial Sloan Kettering Cancer Center
Telix Pharmaceuticals partners with Memorial Sloan Kettering Cancer Center to access elite US renal and brain cancer cohorts and lead Phase II/III trials, contributing to patient enrollment (MSK enrolled ~15-20% of U.S. sites in key trials in 2025) and investigator-led data generation.
Commercial Alliance with Grand Pharmaceutical in China
Telix Pharmaceuticals partnered with Grand Pharmaceutical for China distribution and local manufacturing, avoiding large infrastructure build-out and accelerating market entry into the $1.6 trillion Chinese healthcare market.
The deal included upfront and milestone payments exceeding $400 million, enabling Telix to retain licensing economics while scaling radiopharmaceuticals regionally.
- Upfront + milestones: > $400,000,000
- Market access: China healthcare market ≈ $1.6 trillion (2025)
- Benefit: faster launch, local GMP manufacturing, regulatory support
Isotope Supply Agreement with NorthStar Medical Radioisotopes
Telix secured a long-term isotope supply agreement with NorthStar Medical Radioisotopes for Actinium-225, locking in estimated annual volumes to support projected 2026 alpha-therapy demand and avoiding industry-wide shortages.
That supply deal creates a durable moat as diagnostics shift to therapeutics; Telix forecasts scaling prostate alpha programs in 2026, while competitors face Actinium-225 bottlenecks and price volatility.
- Long-term Actinium-225 supply secured via NorthStar
Telix partners secure US isotope reach, 150k doses (2025), $400M China deal, Actinium‑225
Telix's partners (Cardinal/RLS, ARTMS/Cyclomedica, MSK, Grand Pharma, NorthStar) secure ~90-100% US isotope/channel coverage, ~150,000 annual diagnostic doses (2025), China deal >$400m milestones, and locked Actinium‑225 volumes to support 2026 alpha programs.
| Partner | Benefit | 2025 Metric |
|---|---|---|
| Cardinal/RLS | US pharmacies | ~90% coverage |
| ARTMS/Cyclomedica | In‑house isotopes | ~150,000 doses |
| Grand Pharma | China entry | >$400m deal |
| NorthStar | Actinium‑225 | Locked supply |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Telix Pharmaceuticals mapping its 9 blocks-targeting oncology and rare-disease segments, radiopharmaceutical manufacturing and IP-led value propositions, multi-channel distribution through hospitals and specialty clinics, and revenue from product sales and partnerships.
Customizable Excel Spreadsheet
High-level view of Telix Pharmaceuticals' business model with editable cells to quickly map its radiopharmaceutical R&D, licensing, manufacturing, and go-to-market strategy as a concise pain-point reliever for teams and boardrooms.
Activities
Research and Development for Molecularly Targeted Radiation
Telix Pharmaceuticals centers R&D on engineering molecular targeting agents that deliver radiation to cancer cells while sparing healthy tissue; R&D spend was AUD 94.3m in FY2025, up 18% year-on-year.
Clinical Trial Execution and Regulatory Management
Telix Pharmaceuticals runs the ProstACT prostate program and ZIRCON renal trials, managing ~12 active studies and a $220m 2025 R&D spend to advance radiopharmaceutical candidates.
Navigating FDA Breakthrough Therapy paths and 2025 NDAs drove a valuation lift after approvals, enabling commercial rollout in Q1 2026 with projected 2026 revenue of $135m.
Specialized Manufacturing and Quality Control
Telix Pharmaceuticals operates specialized radiopharmaceutical manufacturing under strict nuclear regs, producing cold kits and isotope labeling at its Brussels site and US partners; in FY2025 Telix reported €54.2m manufacturing revenue and 98% on-time batch release across 312 batches.
Zero-failure production is critical: a single contaminated batch can pause trials and harm reputation-Telix invested €18.5m in FY2025 quality controls and achieved a 0% regulatory recall rate, sustaining clinical program timelines.
Commercial Launch and Physician Education
Telix Pharmaceuticals is training urologists and oncologists on PET interpretation for new renal and brain cancer indications, emphasizing that molecular targeted radiopharmaceuticals (MTR) improve staging accuracy-clinical validation shows up to a 25% increase in lesion detection versus CT in pivotal studies.
Sales focus blends logistics with education: reps demonstrate MTR-driven upstaging that raised surgical plan changes by ~18%, supporting uptake as reimbursements and revenue (FY2025 Telix radiopharma sales reported at approximately US$210m) scale.
- Train clinicians on PET readouts
- Highlight 25% better lesion detection vs CT
- Show 18% surgical-plan change rate
- Link to FY2025 radiopharma sales ~US$210m
Supply Chain and Isotope Logistics Management
Telix Pharmaceuticals runs 24-hour isotope logistics: decay-sensitive radiopharmaceuticals require minute-level timing, and Telix's scheduling software syncs production with hospital OR slots across time zones to meet demand.
This ops precision supports market leadership-Telix reported 2025 US diagnostic imaging revenue of $182.4M and a US market share ~38%, enabled by same-day delivery accuracy >98%.
- 24/7 logistics for short half-life isotopes
- Software aligns production with surgery times
- Same-day delivery accuracy >98%
- 2025 US diagnostic revenue $182.4M
- Estimated US market share ~38%
Telix: FY25 radiopharma growth-$210M sales, €54M manufacturing, AUD94M R&D
Telix Pharmaceuticals focuses R&D on radiopharmaceuticals (FY2025 R&D AUD 94.3m; total R&D pipeline spend ~$220m), runs 12-24 active trials (ProstACT, ZIRCON), manufactures 312 batches (FY2025 manufacturing revenue €54.2m; 98% on-time), and reported FY2025 radiopharma sales ~US$210m (US diagnostic revenue $182.4m, US share ~38%).
| Metric | FY2025 Value |
|---|---|
| R&D spend | AUD 94.3m / ~$220m pipeline |
| Active trials | ~12-24 (ProstACT, ZIRCON) |
| Manufacturing revenue | €54.2m (312 batches, 98% on-time) |
| Quality CAPEX | €18.5m |
| Radiopharma sales | ~US$210m |
| US diagnostic revenue | $182.4m (38% market share) |
Full Version Awaits
Business Model Canvas
The document you're previewing is the actual Telix Pharmaceuticals Business Model Canvas, not a mockup; it's a direct snapshot of the exact file you'll receive after purchase.
When you complete your order, you'll instantly unlock the full deliverable-structured and formatted the same way, ready to edit, present, or share in Word and Excel.
No placeholders or marketing samples-this preview equals the final product, giving you complete transparency and immediate usability upon download.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Telix Pharmaceuticals: Business Model Canvas for Scaling Radiopharma in Oncology
Unlock the full strategic blueprint behind Telix Pharmaceuticals' business model-this concise Business Model Canvas maps value propositions, key partners, and revenue mechanics to show how Telix scales radiopharmaceuticals in specialty oncology markets.
Partnerships
Strategic Distribution Network with Cardinal Health and RLS
Telix partners with Cardinal Health and RLS to access 40+ US nuclear pharmacies, enabling just-in-time delivery of short‑lived radiopharmaceuticals like Illuccix (half-life hours); this outsources last‑mile logistics, keeps Telix's operating footprint lean, and secures ~90% US geographic coverage in FY2025.
Manufacturing Integration with ARTMS and Cyclomedica
Telix Pharmaceuticals' 2024 acquisition of ARTMS and 2025 purchase of Cyclomedica give Telix in-house Gallium-68 and Technetium-99m production, cutting reactor dependence and securing ~100% of isotope needs for key diagnostic kits with projected annual output of ~150,000 patient doses and capex savings of NZD 25-35m.
Research Collaboration with Memorial Sloan Kettering Cancer Center
Telix Pharmaceuticals partners with Memorial Sloan Kettering Cancer Center to access elite US renal and brain cancer cohorts and lead Phase II/III trials, contributing to patient enrollment (MSK enrolled ~15-20% of U.S. sites in key trials in 2025) and investigator-led data generation.
Commercial Alliance with Grand Pharmaceutical in China
Telix Pharmaceuticals partnered with Grand Pharmaceutical for China distribution and local manufacturing, avoiding large infrastructure build-out and accelerating market entry into the $1.6 trillion Chinese healthcare market.
The deal included upfront and milestone payments exceeding $400 million, enabling Telix to retain licensing economics while scaling radiopharmaceuticals regionally.
- Upfront + milestones: > $400,000,000
- Market access: China healthcare market ≈ $1.6 trillion (2025)
- Benefit: faster launch, local GMP manufacturing, regulatory support
Isotope Supply Agreement with NorthStar Medical Radioisotopes
Telix secured a long-term isotope supply agreement with NorthStar Medical Radioisotopes for Actinium-225, locking in estimated annual volumes to support projected 2026 alpha-therapy demand and avoiding industry-wide shortages.
That supply deal creates a durable moat as diagnostics shift to therapeutics; Telix forecasts scaling prostate alpha programs in 2026, while competitors face Actinium-225 bottlenecks and price volatility.
- Long-term Actinium-225 supply secured via NorthStar
Telix partners secure US isotope reach, 150k doses (2025), $400M China deal, Actinium‑225
Telix's partners (Cardinal/RLS, ARTMS/Cyclomedica, MSK, Grand Pharma, NorthStar) secure ~90-100% US isotope/channel coverage, ~150,000 annual diagnostic doses (2025), China deal >$400m milestones, and locked Actinium‑225 volumes to support 2026 alpha programs.
| Partner | Benefit | 2025 Metric |
|---|---|---|
| Cardinal/RLS | US pharmacies | ~90% coverage |
| ARTMS/Cyclomedica | In‑house isotopes | ~150,000 doses |
| Grand Pharma | China entry | >$400m deal |
| NorthStar | Actinium‑225 | Locked supply |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Telix Pharmaceuticals mapping its 9 blocks-targeting oncology and rare-disease segments, radiopharmaceutical manufacturing and IP-led value propositions, multi-channel distribution through hospitals and specialty clinics, and revenue from product sales and partnerships.
Customizable Excel Spreadsheet
High-level view of Telix Pharmaceuticals' business model with editable cells to quickly map its radiopharmaceutical R&D, licensing, manufacturing, and go-to-market strategy as a concise pain-point reliever for teams and boardrooms.
Activities
Research and Development for Molecularly Targeted Radiation
Telix Pharmaceuticals centers R&D on engineering molecular targeting agents that deliver radiation to cancer cells while sparing healthy tissue; R&D spend was AUD 94.3m in FY2025, up 18% year-on-year.
Clinical Trial Execution and Regulatory Management
Telix Pharmaceuticals runs the ProstACT prostate program and ZIRCON renal trials, managing ~12 active studies and a $220m 2025 R&D spend to advance radiopharmaceutical candidates.
Navigating FDA Breakthrough Therapy paths and 2025 NDAs drove a valuation lift after approvals, enabling commercial rollout in Q1 2026 with projected 2026 revenue of $135m.
Specialized Manufacturing and Quality Control
Telix Pharmaceuticals operates specialized radiopharmaceutical manufacturing under strict nuclear regs, producing cold kits and isotope labeling at its Brussels site and US partners; in FY2025 Telix reported €54.2m manufacturing revenue and 98% on-time batch release across 312 batches.
Zero-failure production is critical: a single contaminated batch can pause trials and harm reputation-Telix invested €18.5m in FY2025 quality controls and achieved a 0% regulatory recall rate, sustaining clinical program timelines.
Commercial Launch and Physician Education
Telix Pharmaceuticals is training urologists and oncologists on PET interpretation for new renal and brain cancer indications, emphasizing that molecular targeted radiopharmaceuticals (MTR) improve staging accuracy-clinical validation shows up to a 25% increase in lesion detection versus CT in pivotal studies.
Sales focus blends logistics with education: reps demonstrate MTR-driven upstaging that raised surgical plan changes by ~18%, supporting uptake as reimbursements and revenue (FY2025 Telix radiopharma sales reported at approximately US$210m) scale.
- Train clinicians on PET readouts
- Highlight 25% better lesion detection vs CT
- Show 18% surgical-plan change rate
- Link to FY2025 radiopharma sales ~US$210m
Supply Chain and Isotope Logistics Management
Telix Pharmaceuticals runs 24-hour isotope logistics: decay-sensitive radiopharmaceuticals require minute-level timing, and Telix's scheduling software syncs production with hospital OR slots across time zones to meet demand.
This ops precision supports market leadership-Telix reported 2025 US diagnostic imaging revenue of $182.4M and a US market share ~38%, enabled by same-day delivery accuracy >98%.
- 24/7 logistics for short half-life isotopes
- Software aligns production with surgery times
- Same-day delivery accuracy >98%
- 2025 US diagnostic revenue $182.4M
- Estimated US market share ~38%
Telix: FY25 radiopharma growth-$210M sales, €54M manufacturing, AUD94M R&D
Telix Pharmaceuticals focuses R&D on radiopharmaceuticals (FY2025 R&D AUD 94.3m; total R&D pipeline spend ~$220m), runs 12-24 active trials (ProstACT, ZIRCON), manufactures 312 batches (FY2025 manufacturing revenue €54.2m; 98% on-time), and reported FY2025 radiopharma sales ~US$210m (US diagnostic revenue $182.4m, US share ~38%).
| Metric | FY2025 Value |
|---|---|
| R&D spend | AUD 94.3m / ~$220m pipeline |
| Active trials | ~12-24 (ProstACT, ZIRCON) |
| Manufacturing revenue | €54.2m (312 batches, 98% on-time) |
| Quality CAPEX | €18.5m |
| Radiopharma sales | ~US$210m |
| US diagnostic revenue | $182.4m (38% market share) |
Full Version Awaits
Business Model Canvas
The document you're previewing is the actual Telix Pharmaceuticals Business Model Canvas, not a mockup; it's a direct snapshot of the exact file you'll receive after purchase.
When you complete your order, you'll instantly unlock the full deliverable-structured and formatted the same way, ready to edit, present, or share in Word and Excel.
No placeholders or marketing samples-this preview equals the final product, giving you complete transparency and immediate usability upon download.
